Nisa Leung is a Managing Partner of Qiming Venture Partners and leading its health care investments. Qiming Venture Partners is a leading investment firm in China which currently manages over USD 4 billion in assets and investment in over 250 companies.
Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ: SCLN) and U-Systems (acquired by GE Healthcare). Nisa was Venture Partner of PacRim Ventures in Menlo Park, and was previously with Softbank/Mobius Venture Capital.
Nisa was named Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017. She currently sits on the board of Gan & Lee Pharmaceutical, Zai Laboratories (NASDAQ: ZLAB), Nurotron, Venus MedTech, Goodwill Information Technology, dMed, LIH Rehabilitation, CanSino Biotechnology, Berry Genomics (SZSE:000710). She also oversees Qiming’s investments in Acea Biosciences, Aeonmed Medical, CITIC Pharmaceuticals (acquired by Shanghai Pharmaceutical HKSE: 02607), Crown Bioscience (GTSM: 6554), Origene Technologies (acquired by VCAN Bio SHSE: 600645), Richen, Wuxi Leiming, Chain Medical Labs, Suzhou Qiagen, Jacobio and New Horizon Bio.
Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School, a founding member and Vice Chair of PhIRDA (China Pharmaceutical Innovation and Research Development Association) Investment Committee, member of Committee on Hong Kong Innovation and Technology (I&T) Development and Re-Industrialization, advisor of Our Hong Kong Foundation, convener of Venture Investors Alliance of Hong Kong, council member of HKUST Business School and she serves on the Board of Governors of the Hotchkiss School and the Hong Kong Palace Museum.